Market Flash on RGC
EquiLend Data & Analytics identifies Regencell Bioscience as a prime short squeeze candidate, with its short squeeze score at 88.
About US
Separating Signal from Noise
Orbisa is built specifically for hedge fund managers to gain transparency across their portfolio, add depth to buy-side trading analysis by providing strategic insights and validate market sentiment across the wider industry.
Utilization, short interest ratio, new loans, on-loan value, returns and rerates, duration (days to cover) and other key metrics are available, offering a comprehensive view of the market’s outlook on specific securities.
By analyzing short interest data, Orbisa delivers deep insights into the wholesale securities lending market, including exclusive analysis around broker-to-broker activity and borrower and lender depth as multiple indicators of the wider lending community.
The Orbisa Real-Time Data package provides users with an exclusive view of intraday securities lending and sentiment data for a given security.
Orbisa Sentiment Data provides users with enhanced market color and insight into retail trader sentiment for individual securities by analyzing social media volume, short squeeze mentions and a time-weighted sentiment score.
Our Latest Insights
Orbisa on JNVR
EquiLend Data & Analytics identifies Janover Inc as a prime short squeeze candidate, as the EquiLend Short Squeeze Score surged to 86 indicating extreme potential for continued short covering.
Orbisa on SMMT
EquiLend Data & Analytics identifies Summit Therapeutics as a prime short squeeze candidate, with its squeeze score surging 43.0 points to 66 in just one month. With utilization approaching 78.98% and elevated borrow fees, short sellers are facing mounting pressure as positive clinical trial results drive momentum.